HCPCS code Q4182: Transcyte billing and fee schedule guide

HCPCS code Q4182 is the Level II code for Transcyte, a biosynthetic skin substitute, billed per square centimeter to Medicare and commercial payers. Units equal the wound area treated, and the supply code only pays when a CPT application code from the 15271-15278 series rides with it.

This reference covers the official descriptor, the fee schedule by setting, and the application code pairings. It also sets out the coverage rules and the documentation a payer expects before it pays a Q4182 line.

Found our content helpful?

Key takeaways

HCPCS code Q4182 describes Transcyte, a biosynthetic skin substitute, reported per square centimeter to Medicare and most commercial payers.

Q4182 has to be paired with a CPT application code from the 15271-15278 series, because the supply code alone is denied.

The anatomic site and the total wound surface area decide which of the eight application codes applies.

Wound measurements in square centimeters belong in the clinical record before every Q4182 claim is submitted.

Pabau’s claims management software keeps per-unit quantities with the encounter that produced them, so clean claims go out first time.

Q4182 descriptor, classification, and code attributes

Q4182 is a Level II HCPCS supply code for Transcyte skin substitute, billed per square centimeter. The Centers for Medicare and Medicaid Services (CMS) maintains it as part of the Q4100 series, which covers skin substitute graft products. Payment runs through the Outpatient Prospective Payment System (OPPS) or the Medicare Physician Fee Schedule (MPFS), depending on the setting. CMS publishes the full HCPCS Level II code set annually, and the CMS HCPCS overview is the authoritative source for code structure and maintenance.

The supply code reports the product. A separate application procedure code reports the work of applying it, and sequencing the two correctly is what keeps the claim payable.

Wound care billing sits alongside scheduling and clinical documentation, so a practice running all three in one system spends less time reconciling them. Claims management software keeps each per-unit quantity attached to the encounter it came from.

What is Transcyte? Clinical overview

Transcyte is a biosynthetic wound dressing that works as a temporary skin substitute. It lays a biologically active matrix over partial-thickness burns and chronic wounds while the patient’s own skin regenerates. Advanced Tissue Sciences developed the product and obtained FDA premarket approval for it in March 1997.

Clinically, Transcyte is indicated for partial-thickness burns, donor sites, and selected chronic wound types where a temporary barrier is needed. Key product characteristics relevant to billing and coverage decisions include:

• Composition: Human neonatal fibroblasts grown on a nylon mesh coated with porcine collagen
• Classification: Biosynthetic temporary wound covering, not a permanent skin graft
• Storage and handling: Cryopreserved; requires a specific thawing protocol per manufacturer instructions
• FDA status: Premarket approval P960007, granted March 1997. Transcyte was approved through the PMA pathway, not cleared under 510(k)
• Ownership history: Smith and Nephew acquired the product in 2002 after Advanced Tissue Sciences went bankrupt, then sold it to Advanced BioHealing in 2006
• Coverage context: Payers distinguish between temporary skin substitutes and permanent grafts, and correct classification is required for Q4182 coverage

Confirm current availability with the product’s present distributor, and check that the treating facility used Transcyte itself, before assigning HCPCS code Q4182. Applying Q4182 to a different skin substitute is a misrepresentation that payers will recoup on audit.

Medicare fee schedule and reimbursement for Q4182

Medicare reimburses Q4182 per square centimeter of Transcyte applied. Allowable amounts vary by setting, by geographic locality, and by Medicare Administrative Contractor (MAC) jurisdiction. CMS publishes updated rates annually, and the current figures are available through the CMS Physician Fee Schedule lookup.

Because allowables are per square centimeter, the units billed have to equal the wound area treated. Rounding up, or billing a stock package quantity instead of the measured area, is a common audit trigger. Verify your MAC’s current allowable for Q4182 before setting internal fee schedules.

How to bill Q4182: Application codes and modifiers

HCPCS code Q4182 reports the Transcyte product itself. A separate CPT application code from the 15271-15278 series reports the work of applying the skin substitute. Both codes belong on the same claim, and Q4182 submitted on its own is usually denied. Getting that pairing right on the first submission is most of what a clean claim takes here.

CPT application codes that pair with Q4182

Two questions settle the choice. The first is which anatomic group the wound sits in, and the second is whether total wound surface area reaches 100 sq cm.

For infants and children, the descriptors on 15273, 15274, 15277 and 15278 express the same thresholds as a percentage of body area. No descriptor in this family distinguishes an acellular dermal replacement from any other skin substitute.

Quantity reporting and modifiers

Report Q4182 units as the total wound area in whole square centimeters. A wound measuring 12.4 sq cm is billed as 12 units, because rounding up inflates the quantity and creates a billing error. The AAPC HCPCS code lookup and the NLM HCPCS Level II API are useful for verifying code descriptors and attributes.

Common modifiers and claim-level fields used with Q4182 include:

• Modifier 59 (distinct procedural service): Separates two non-E/M procedures performed in the same session that a payer would otherwise bundle. It never applies to an evaluation and management service billed alongside Q4182, which is modifier 25’s job
• Modifier KX (requirements specified in the medical policy have been met): Attests that the MAC’s skin substitute LCD criteria are satisfied. Several MACs require it from the fifth application onward in a treatment episode
• Modifier GY (item or service statutorily excluded): Used when a non-covered service is billed so the denial can be issued
• Place of service 11 (office) or 22 (on-campus outpatient hospital): Required on the claim, and it changes the payment rate

Verify modifier applicability against your MAC’s current LCD for skin substitute grafts. Requirements differ by region, and they are revised more often than the code set is.

Coverage requirements and prior authorization

Medicare coverage for Q4182 depends on the applicable MAC Local Coverage Determination (LCD) for skin substitute grafts. No national coverage determination (NCD) exists for Q4182 specifically. Prior authorization (PA) requirements vary:

• Medicare: PA is generally not required under traditional Medicare, though some MACs impose it on high-cost skin substitutes. Check with your own MAC.
• Medicare Advantage: Requirements vary by plan. Many plans treat high-cost skin substitutes as requiring prior authorization regardless of traditional Medicare policy.
• Commercial payers: Prior authorization is commonly required. Confirm plan by plan before application, since performing the procedure without an approval creates collection risk.
• Medicaid: Coverage and PA requirements vary by state. Several state programs cover Transcyte for burns, while others require a separate coverage determination.

Check eligibility and prior authorization before the procedure, not after it. A benefits check confirms active coverage and surfaces any approval the plan expects on a high-cost skin substitute. Applying Transcyte first and asking later leaves the practice holding the cost when the payer refuses.

Documentation requirements for Q4182

Post-payment audits on Q4182 usually turn on the medical record rather than the code itself. The table below maps each documentation element to the billing purpose it serves. It also names where in the chart an auditor expects to find it.

Many MAC LCDs for skin substitutes require evidence that standard wound care was tried for four weeks first. A missing treatment history is the most common reason an otherwise valid Q4182 claim fails on audit. Pull the prior visit notes into the record before the claim goes out, rather than after a recoupment letter arrives.

Related skin substitute HCPCS codes in the Q4100 series

The Q4100 series covers the skin substitute graft supply codes. When the product applied is not Transcyte, the correct code is the Q4-series code specific to that product, and billing Q4182 instead is a misrepresentation. Use the table below to identify the adjacent codes for commonly applied skin substitutes.

ICD-10 diagnosis codes used with Q4182

Q4182 claims require a supporting ICD-10-CM diagnosis code on the same claim. The diagnosis has to reflect the wound type that justifies applying Transcyte. The codes below are the ones most consistently paired with Q4182 in wound care settings. When the wound type falls outside this list, our ICD-10-CM codes library covers the wider set.

Select the most specific ICD-10-CM code available for the wound type, site, and severity. Reaching for an unspecified code when a more specific one exists is a red flag on claim review. Confirm each code is active for the date of service, since ICD-10-CM updates take effect on October 1.

How Pabau keeps Q4182 units and documentation in step

In most wound care practices the measurement and the claim live in different places. A clinician writes the wound area into the procedure note, and a biller keys the unit count onto the claim. Nobody compares the two until a payer asks for the record.

Practice management software like Pabau keeps the encounter and the claim on one patient record. The wound measurement captured in the clinical note stays attached to the charge. That makes the Q4182 unit count traceable to the note that justifies it. The application CPT code and the supporting diagnosis sit on the same encounter.

That means a documentation request is answered from one place instead of three. Claim status is visible as it moves, so a rejected Q4182 line is corrected while the filing window is still open.

Wound care billing getting complex?

Pabau’s claims management tools help wound care practices keep per-unit quantities with the encounter they came from. They pair supply and procedure codes so clean claims go out the first time. See how it works with a short demo.

Book a demo

Conclusion

Q4182 is a simple code with an unforgiving paper trail. The descriptor, the units, and the application code are quick to get right. What decides whether the payment survives a look back two years later is the record behind them.

So the work worth doing sits upstream of the claim. Fix how the wound measurement reaches the note, and the unit count on the claim stops being a judgment call. The rest is transcription.

Pabau keeps the wound measurement, the application code, and the claim on one patient record. Book a demo to see how Pabau tracks per-unit supply codes alongside the clinical notes that justify them.

Continue your research

Need to understand how denial codes affect wound care claims? Denial codes in medical billing explains the most common remittance advice codes and how to respond to them.

Want to build a cleaner claims submission workflow? Electronic remittance advice covers how ERAs streamline payment posting and denial tracking for billing teams.

Looking for a broader guide to wound care billing compliance? Revenue cycle management fundamentals walks through the full claims process from coding to payment reconciliation.

New to the claims lifecycle behind a supply code? What is medical billing follows a claim from the encounter through to payment posting.

Worried about audit exposure on high-cost supplies? Medical billing compliance sets out the documentation standards that hold up under post-payment review.

Frequently asked questions